Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corporation (ADPT +2.10%), reported the exercise of 14,707 options and immediate sale of 19,037 shares of common stock on April 27, 2026 for a total value of approximately $271,000, as disclosed in the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 19,037 |
| Transaction value | ~$271,000 |
| Post-transaction shares (direct) | 377,802 |
| Post-transaction value (direct ownership) | ~$5.37 million |
Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($14.23).
Key questions
- What portion of Rubinstein's direct stake was impacted by this option-related sale?
The 19,037 shares sold represented 4.8% of Rubinstein's direct common stock holdings as of the transaction date, reflecting a modest reduction in her direct equity exposure. - How does the derivative context shape this transaction?
This filing involved the exercise of 14,707 stock options and immediate disposition of the resulting shares, meaning the transaction reflects a conversion-for-sale rather than a reduction of previously held common shares. - What is the remaining ownership position after this trade?
Following the sale, Rubinstein holds 377,802 shares of common stock directly and 45,731 stock options (direct), maintaining a continuing economic interest in the company beyond the shares sold. - Does this transaction represent a change in trading cadence or capacity?
Rubinstein's direct share count has declined materially over the past year, and the smaller sale size in this event is explained by the reduced available share base, not a discretionary slowdown in activity.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $276.98 million |
| Net income (TTM) | ($59.50 million) |
| Employees | 619 |
Company snapshot
- Adaptive Biotechnologies offers immunosequencing and diagnostic platforms such as immunoSEQ, clonoSEQ, and T-Detect, with a focus on cancer, autoimmune, and infectious disease applications.
- It generates revenue from product sales, clinical diagnostics, and strategic collaborations in immune medicine and drug discovery.
- The company serves life sciences researchers, clinical laboratories, pharmaceutical developers, and healthcare providers.
Adaptive Biotechnologies Corporation is a biotechnology company specializing in immune-driven diagnostics and therapeutic platforms, with a market presence in both research and clinical settings.
The company leverages proprietary immunosequencing technology and strategic partnerships to address unmet needs in disease diagnosis and monitoring. Its integrated approach and collaborations with industry leaders position it as a key innovator in immune medicine.
What this transaction means for investors
The April 27 sale of Adaptive Biotechnologies stock by Chief Operating Officer Julie Rubinstein is not a red flag for investors. She executed the transaction as part of her Rule 10b5-1 trading plan adopted in November of 2025. Such plans are often implemented by executives to avoid accusations of making trades based on insider information.
In addition, Rubinstein maintained a significant equity stake in the company. Post-transaction, she had 377,802 directly-held shares along with 45,731 stock options. This suggests she is not rushing to dispose of her holdings.
Adaptive Biotechnologies stock went on a run in 2025, reaching a 52-week high of $20.76 last November, but has since pulled back. The drop in share price makes sense since it had reached a lofty valuation, as evidenced by a price-to-sales ratio exceeding 12 last year.
Adaptive Biotechnologies exited 2025 with sales of $277 million, representing a strong 55% increase over the prior year. It had an operating loss of $57.1 million in 2025, but that’s a significant reduction from 2024’s loss of $162.5 million. However, the company expects a modest increase in operating costs in 2026.
With the stock price’s drop, now may be an opportunity to buy shares, if you believe the company can continue to grow sales while keeping its costs under control.
